<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04310943</url>
  </required_header>
  <id_info>
    <org_study_id>CROC2003</org_study_id>
    <nct_id>NCT04310943</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Tislelizumab Combined With Bevacizumab and Albumin Paclitaxel in Lung Adenocarcinoma</brief_title>
  <official_title>Tislelizumab Combined With Bevacizumab and Albumin Paclitaxel in the Treatment of Advanced Lung Adenocarcinoma: a Single-arm, Phase Ⅱ Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhou Chengzhi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangzhou Institute of Respiratory Disease</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The single arm clinical study is to evaluate the efficacy and safety of Tislelizumab combined
      with Bevacizumab and albumin paclitaxel in the treatment of advanced lung adenocarcinoma. All
      of the patients were received EGFR-TKI therapy for 1 line and disease progression. The
      primary endpoint is one-year PFS rate and safety, the seconday endpoint is ORR and one-year
      OS rate.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who meet the inclusion criteria will receive Tislelizumab combined with Bevacizumab
      and albumin paclitaxel for 4 cycles. If there is no disease progression, the patient will
      continue to receive Tislelizumab maintenance therapy, until the disease progresses or death.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS rate</measure>
    <time_frame>one year</time_frame>
    <description>rate of progression free survical in one year</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of Tislelizumab</measure>
    <time_frame>30 days after the trial finished</time_frame>
    <description>TEAE are adverse events that occur during or after the first administration of the study drug until 30 days after the study drug is discontinued or the new anticancer treatment is initiated or worse than at baseline (before treatment)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>one year</time_frame>
    <description>objective response rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS rate</measure>
    <time_frame>one year</time_frame>
    <description>rate of oversurvival rate</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Lung Adenocarcinoma Stage IV</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tislelizumab (200mg,Q3W )+Bevacizumab(15 mg/kg,Q3W)+Albumin paclitaxel(100mg/m2,d1,8,15) for 4 cycles, and if there is no disease progression, patients will receive Tislelizumab(200mg,Q3W) until progression or death.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tislelizumab</intervention_name>
    <description>Tislelizumab, 200mg, Q3W ,use until disease progression</description>
    <arm_group_label>Arm 1</arm_group_label>
    <other_name>Albumin paclitaxel</other_name>
    <other_name>Bevacizumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  lung adenocarcinoma stage Ⅳ(according AJCC 8)

          -  received EGFR-TKI for 1 line and disease progression

          -  EGFR T790M negative

          -  ECOG PS 0-1

        Exclusion Criteria:

          -  histology of mixed NSCLC with squamous cell carcinoma, neuroendocrine carcinoma and
             small cell carcinoma.

          -  have received checkpoint inhibitor.

          -  uncontrolled pleural effusion, pericardial effusion, or ascites after appropriate
             intervention

          -  any unstable systemic disease

          -  patients who were treated with systemic glucocorticoids (&gt;10mg/ day prednisone
             therapeutic dose) or other immunosuppressive drugs within 14 days prior to the initial
             administration or during the study period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zhou Chengzhi, Doctor</last_name>
    <phone>(+86)13560351186</phone>
    <email>doctorzcz@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhou Chengzhi</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Chengzhi Zhou, Professor</last_name>
      <phone>13560351186</phone>
      <email>doctorzcz@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity. 2013 Jul 25;39(1):74-88. doi: 10.1016/j.immuni.2013.06.014. Review.</citation>
    <PMID>23890065</PMID>
  </reference>
  <reference>
    <citation>Wallin JJ, Bendell JC, Funke R, Sznol M, Korski K, Jones S, Hernandez G, Mier J, He X, Hodi FS, Denker M, Leveque V, Cañamero M, Babitski G, Koeppen H, Ziai J, Sharma N, Gaire F, Chen DS, Waterkamp D, Hegde PS, McDermott DF. Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma. Nat Commun. 2016 Aug 30;7:12624. doi: 10.1038/ncomms12624.</citation>
    <PMID>27571927</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 13, 2020</study_first_submitted>
  <study_first_submitted_qc>March 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2020</study_first_posted>
  <last_update_submitted>March 16, 2020</last_update_submitted>
  <last_update_submitted_qc>March 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Guangzhou Institute of Respiratory Disease</investigator_affiliation>
    <investigator_full_name>Zhou Chengzhi</investigator_full_name>
    <investigator_title>Chief Physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Adenocarcinoma of Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

